ReviewIET systems biology
Gut Microbiome and Paediatric Inflammatory Bowel Disease: Emerging Mechanistic and Therapeutic Insights Into Pathogenesis and Microbiota-Based Approaches.
Review in IET systems biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Infliximab-linked gut microbiome signatures as candidate treatment response biomarkers in pediatric inflammatory bowel disease: a systematic review.Frontiers in pharmacology · 2026Pooled it
- Integrated Multi-Omics Reveals Complementary Luminal and Mucosal Host-Microbiome Interactions Associated with Disease Activity and Phenotype in Paediatric Inflammatory Bowel Disease.Microorganisms · 2026Article
- Gut feelings and sweet teeth: nutritional solutions to the gut damage in inflammatory bowel disease and HIV infection.Frontiers in nutrition · 2026Review
- Gut Microbiome and Paediatric Inflammatory Bowel Disease: Emerging Mechanistic and Therapeutic Insights Into Pathogenesis and Microbiota-Based Approaches.IET systems biologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The gut microbiome is crucial for paediatric intestinal development and holds therapeutic potential for inflammatory bowel disease (IBD). This review explores the link between gut microbiome dysbiosis and paediatric IBD pathogenesis. Microbial colonisation during early developmental windows establishes immune tolerance, reinforces epithelial barrier integrity and regulates metabolic functions. Dysbiosis contributes to disease through reduced beneficial microbial metabolites, impaired mucosal barriers and aberrant immune activation. Distinct dysbiosis signatures in paediatric patients correlate with clinical phenotypes and treatment responses, suggesting potential biomarkers. Emerging therapies include targeted nutritional therapies, designed microbial consortia, microbiota transplantation and tailored diets. By correcting underlying microbial imbalances, these approaches may offer more sustainable disease control with fewer side effects than conventional anti-inflammatory treatments. However, challenges persist, such as limited paediatric cohort sizes, a lack of causal mechanistic data and variability in microbiome profiles due to diet, geography and developmental stage. Future research requires larger longitudinal studies to develop paediatric-specific interventions that restore microbial equilibrium, ultimately transforming IBD management in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.